DexCom, Inc. (DXCM)
DexCom, Inc. is a medical device company specializing in continuous glucose monitoring (CGM) systems for people with diabetes. Founded in 1999, the company develops innovative technologies that provide real-time glucose readings to help manage blood sugar levels more effectively. DexCom's products are used by patients and healthcare professionals worldwide to improve diabetes management and reduce complications associated with the condition.
Company News
BlackRock Health Sciences Term Trust (BMEZ) recently cut its dividend, but still offers a 9.2% monthly yield. The fund focuses on healthcare innovators that could benefit from potential policy changes, with top holdings in biotech and medical technology companies.
Vancouver-based advertising agency Wasserman has rebranded to 9Letters, emphasizing a strategic shift to adapt to the evolving marketing landscape by enhancing data analysis and investing in new talent.
Despite recent stock performance challenges, PayPal and DexCom show promising long-term investment potential due to strong market positioning, technological innovation, and growth opportunities in digital payments and medical technology.
Tandem Diabetes Care reported a Q2 loss of $0.78 per share, missed earnings estimates, and announced a voluntary medical device correction for t:slim X2 insulin pumps due to potential speaker-related issues affecting insulin delivery.
DexCom, Inc. is scheduled to release its second-quarter 2024 results on July 25. The company's revenues are expected to grow 19% year-over-year, driven by increased product volume and global awareness of its continuous glucose monitoring system. However, rising costs and competition may have weighed on its performance.
